Placebo News and Research

RSS

British researchers call for WHO to 'condemn homeopathy' for serious diseases

British researchers on Monday requested the WHO "publicly condemn homeopathy as a treatment for serious diseases, such as HIV/AIDS, TB and malaria," amid growing concern that some patients are dying as a result of choosing homeopathy over effective medicines, the Mail & Guardian reports. "The WHO works with national organisations that promote homeopathy and other alternative medicines in their public health programmes," according to the Mail & Guardian.

2 Jun 2009

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

1 Jun 2009

Citalopram no more effective than a placebo for children with autism spectrum disorders

Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes. The study was published in the June 2009 issue of Archives of General Psychiatry.

1 Jun 2009

The effectiveness of Tai Chi for chronic musculoskeletal pain conditions

The results of a new analysis have provided good evidence to suggest that Tai Chi is beneficial for arthritis. Specifically, it was shown to decrease pain with trends towards improving overall physical health, level of tension and satisfaction with health status.

1 Jun 2009

Drug combo improves outcome for advanced non-small cell lung cancer

A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC).

1 Jun 2009

FDA approves Reclast (zoledronic acid) for osteoporosis in postmenopausal women

Reclast (zoledronic acid) Injection has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast is already approved as a once-yearly infusion for the treatment of postmenopausal osteoporosis.

1 Jun 2009

Iressa (gefinitib) chemotherapy combination proves safe for head and neck cancer patients

Patients undergoing treatment for advanced head and neck cancers may respond well to the addition of gefinitib to chemotherapy, according to a study sponsored by the Eastern Cooperative Oncology Group and chaired by Ethan Argiris, M.D., associate professor of medicine, University of Pittsburgh School of Medicine, and co-leader of the Head and Neck Cancer Program of the University of Pittsburgh Cancer Institute (UPCI).

31 May 2009

Catalyst Pharmaceutical Partners announces top-line results of CPP-109 phase II trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. has announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction.

31 May 2009

Diabetes-related amputations can be reduced

Using fenofibrate to lower blood fats in people with diabetes reduces the risk of a first diabetes-related amputation by 36 per cent. This is among the conclusions of the FIELD study, reported in an article in this week's diabetes special issue of The Lancet.

27 May 2009

Diabetes drug pioglitazone shows potential against multiple sclerosis

A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology.

26 May 2009

Inositol protects against the development of neural tube defects

Women of childbearing age can reduce the risk of having a child born with a neural tube defect such as spina bifida by eating enough folate or folic acid. However, folate prevents only about 70 percent of these defects.

25 May 2009

FDA approves Samsca (tolvaptan) to treat hyponatremia

The U.S. Food and Drug Administration has approved Samsca tablets (tolvaptan) to treat hyponatremia, an abnormally low concentration of sodium in the blood.

22 May 2009

Comparison key to lower drug costs, better outcomes

Patients can expect significant savings and better outcomes from their prescription medications when health care professionals use comparative effectiveness research, according to researchers at the University of Illinois at Chicago.

22 May 2009

Aspirin and an anti-clotting drug ‘combo’ reduces risk of dialysis access failure

For the first time, a combination of aspirin and the anti-platelet drug dipyridamole has been shown to significantly reduce blockages and extend the useful life of new artery-vein access grafts used for hemodialysis, according to a study by the Dialysis Access Consortium (DAC).

21 May 2009

Trial tests potential new angina treatment

As part of a multi-center clinical trial, UC San Diego Medical Center is evaluating the safety and effectiveness of a potential new way to treat angina - by injecting a protein that stimulates the growth of new oxygen-rich blood vessels directly into the heart. Angina is a debilitating form of chest pain caused by coronary artery disease that affects more than nine million Americans.

20 May 2009

Comparative effectiveness necessary to weigh new drugs against old ones, opinion piece says

Patients and physicians "need to know not just whether a new drug outperforms a placebo, but whether it's a real advance on what's already on the market," Richard Friedman, a professor of psychiatry at Weill Cornell Medical College, writes in a New York Times opinion piece.

20 May 2009

Sucampo Pharmaceuticals initiates phase 3 trial of Lubiprostone for chronic idiopathic constipation in Japan

Sucampo Pharmaceuticals, Inc. today announced that its subsidiary, Sucampo Pharma, Ltd., has initiated enrollment and completed the randomization of the first patient into the pivotal phase 3 efficacy trial of lubiprostone for chronic idiopathic constipation (CIC) in Japan.

20 May 2009

A new path for cocaine addiction research

Cocaine is one of the oldest drugs known to humans, and its abuse has become widespread since the end of the 19th century. At the same time, we know rather little about its effects on the human brain or the mechanisms that lead to cocaine addiction.

19 May 2009

HRT-breast cancer risk stays same, regardless of family history

The risk of developing breast cancer due to taking hormone replacement therapy appears to be the same for women with a family history of the disease and without a family history, a University of Rochester Medical Center study concluded.

19 May 2009

Biovail acquires worldwide rights to Tetrabenazine

Biovail Corporation today announced a wholly owned subsidiary has entered into a definitive agreement to acquire worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman (tetrabenazine tablets), and the associated intellectual property rights held by Cambridge Laboratories (Ireland) Ltd and its affiliates.

18 May 2009